Can Vistagen turn refisolone into a fast-acting alternative for menopausal hot flashes?
Vistagen advances refisolone for menopausal hot flashes after FDA clearance. Find out what this means for non-hormonal treatment options.
Pharma & Biotech
Pharma & Biotech
How OrganaBio’s RxMP partnership could advance RMP-402 for severe bleeding control
Find out how OrganaBio’s RxMP partnership could advance RMP-402, a first-in-class therapy for severe bleeding control.
Pharma & Biotech
Why DemeRx’s FDA-cleared DMX-1001 IND could matter for alcohol use disorder drug development
Find out how DemeRx’s DMX-1001 IND acceptance could reshape alcohol use disorder drug development and what risks remain.
Pharma & Biotech
Can logic-gated CAR T therapies finally crack solid tumors? A2 Biotherapeutics shares early ASCO data
A2 Biotherapeutics shares EVEREST-2 CAR T data at ASCO 2026. Find out what this means for solid tumor therapy and next-gen cell treatments.
Medical Devices & Diagnostics
Could Reflow Medical’s new Cora microcatheters fix a hidden pain point in complex PCI?
Find out how Reflow Medical’s Cora Flex and Cora Force launch could reshape complex coronary intervention workflows.
Medical Devices & Diagnostics
Can Anaxiom’s AVOS device open a new minimally invasive route in obesity treatment?
Find out how Anaxiom’s AVOS obesity device could reshape minimally invasive weight-loss treatment after early human results.
Pharma & Biotech
Is lysergide finally going mainstream? Definium Therapeutics bets on DT120 ODT clinical momentum
Can DT120 ODT transform mental health treatment? Explore Definium Therapeutics’ pivotal trials and what they mean for psychedelic psychiatry.
Medical Devices & Diagnostics
Could XVIVO’s HOPE data change how long donor hearts can survive outside the body?
See how XVIVO’s PRESERVE Trial data could reshape donor heart preservation, FDA review, and transplant access.
Pharma & Biotech
Is this the migraine breakthrough Big Pharma missed? Kallyope’s elismetrep hints at a whole new treatment playbook
Kallyope’s elismetrep migraine data point to a new TRPM8 treatment pathway. Find out what Phase 3 could prove next.
Pharma & Biotech
What Epitopea’s MHRA-approved OVACT trial signals for off-the-shelf cancer vaccines
Find out how Epitopea’s CryptiVax-1001 trial could reshape RNA cancer vaccines and ovarian cancer treatment strategies.